Core Viewpoint - The Hong Kong stock market is expected to perform well in 2025, with the Hang Seng Index and Hang Seng Tech Index leading global stock markets, driven by valuation attractiveness and structural changes in the economy [1] Investment Strategy - The investment strategy of the fund manager focuses on growth style, with a balanced approach that does not exceed 25% in any single industry, emphasizing valuation and a bottom-up investment approach [2][3] - The manager's investment philosophy includes three main characteristics: a growth-oriented style, balanced investment across sectors, and a focus on valuation [2][3] Stock Selection Framework - The stock selection framework is based on three dimensions: competitive barriers, market conditions, and valuation [3][4] - Competitive barriers are prioritized, focusing on business models and corporate culture, with an emphasis on differentiation and scale effects [3] - Market conditions are particularly important for TMT companies, while valuation is assessed using a five-year implied return to evaluate cost-effectiveness [4] Market Outlook - The outlook for the A-share market remains positive, with a focus on technology sectors such as 3D stacking, semiconductor manufacturing, and cloud computing [4] - The Hong Kong market is expected to benefit from economic stabilization and a potential influx of foreign capital due to the U.S. interest rate cuts [5][6] Investment Focus - The investment focus is on identifying companies with clear alpha characteristics rather than merely chasing beta trends, particularly in the context of small-cap stocks in the Hong Kong market [6] - The manager emphasizes the importance of free cash flow and believes that the valuation of leading companies in the Hong Kong market presents strong cost-effectiveness [5][6] Innovation Drug Sector - The innovation drug sector has entered a long-term reversal phase, with significant growth potential as leading companies achieve breakeven and improve self-sustainability [6][7] - The investment strategy in the innovation drug sector is shifting towards leading companies, with a focus on business development and commercialization stages [7]

Group 1 - Public funds in the pharmaceutical sector have shown significant excess returns, with an average net value growth rate exceeding 19% as of June 18, making it a market focus [1][3] - The average net value growth rate for all public funds is 2.83%, while over 260 pharmaceutical-related funds have achieved an average growth rate of 19.66%, indicating strong profitability [1][3] - Among the top 100 funds by performance, pharmaceutical funds occupy 49 positions, highlighting their strong earning effect [1] Group 2 - Funds specifically focused on "innovative drugs" have performed exceptionally well, with an average net value growth rate of 27.68%, and 21 funds exceeding 20% growth [3] - Key factors driving the strong performance of the pharmaceutical sector, particularly innovative drugs, include supportive policies such as improved drug procurement mechanisms and accelerated new drug approvals [3] - The period from 2025 to 2028 is critical for Chinese innovative drug companies to enter profitability, with 2025 being a pivotal year for the industry [3] Group 3 - Increased collaboration between domestic innovative drug companies and multinational pharmaceutical firms reflects the global competitiveness of China's innovative drug sector [4] - Fund managers are optimistic about the long-term investment value of the innovative drug sector, citing improved valuation post-adjustment and enhanced R&D efficiency due to domestic talent [3][4] - The government’s influence on drug procurement is diminishing, further supporting the growth potential of the innovative drug sector [3]

Group 1 - The core viewpoint is that pharmaceutical funds have significantly outperformed the market, with an average net value growth rate of over 19% as of June 18, making them a focal point for investors [1][2] - Among all public funds, pharmaceutical funds accounted for 49 out of the top 100 funds in terms of performance, indicating strong interest and investment potential in this sector [2] - The average net value growth rate for pharmaceutical funds reached 19.66%, with several funds achieving around 70% growth, particularly those focused on innovative drugs [2] Group 2 - Key driving factors for the pharmaceutical sector's performance include supportive policies such as improved drug procurement mechanisms and accelerated new drug approval processes [3] - The period from 2025 to 2028 is projected to be critical for Chinese innovative drug companies, with 2025 expected to be a pivotal year for profitability [3] - The innovative drug sector is anticipated to enter a sustained growth cycle, driven by clinical catalysts and significant financial performance improvements [3] Group 3 - Fund managers express optimism about the innovative drug sector, highlighting its growth potential and the favorable policy environment that provides substantial development space for pharmaceutical companies [4] - The innovative drug sector is seen as undervalued, with many companies now presenting attractive valuations, leading to increased investment interest [4] - Recent performance in the innovative drug sector is attributed to the market's recognition of the value of high-quality Chinese innovative drug assets [4] Group 4 - Collaborations between domestic innovative drug companies and multinational pharmaceutical firms are enhancing the global competitiveness of Chinese innovative drugs, prompting a reassessment of their pipeline values [5]